

Handwritten: *St 4*  
*Chen*  
*5/20*  
JC14 Rec'd PCT/PTO 09 MAY 2002

Practitioner's Docket No. MWH-002US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew, et al.  
Application No.: 10/010,802  
Filing Date: November 9, 2001

Art Unit: 1614  
Examiner: to be assigned

For: Drug Target Isogenes: Polymorphisms in the Interleukin-4  
Receptor Alpha Gene

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

Enclosed herewith please find:

1. Identification of Time of Filing the Accompanying Information Disclosure Statement
2. Information Disclosure Statement by Applicant Form PTO/SB/08A (1 page)
3. Information Disclosure Statement by Applicant Form PTO/SB/08B (3 pages)
4. Copies of Listed References Accompanying this Statement (24-Total)

Date: 8-May-2002  
Tel. No. 203-786-3468  
Registration No. 47,934  
Customer No. 25106

Sandra L. Shaner  
Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10\*  
(Express Mail label number is *mandatory*.)  
(Express Mail certification is *optional*.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on May 9, 2002 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL S74 S9S14 S US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox  
(type or print name of person mailing paper)  
*Cathy Wilcox*  
Signature of person mailing

Practitioner's Docket No. MWH-002US2

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Chew, et al.	Art Unit:	1614
Application No.:	10/010,802	Examiner:	to be assigned
Filing Date:	November 9, 2001		


For: Drug Target Isogenes: Polymorphisms in the Interleukin-4  
Receptor Alpha Gene

Assistant Commissioner for Patents  
Washington, D.C. 20231

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 197(b).

Date: 8-May-2002  
Tel. No. 203-786-3468  
Registration No. 47,934  
Customer No. 25106

  
Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/2900

MAY 20 2002

RECEIVED

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
			Application Number	10/010,802
			Filing Date	11/09/2001
			First Named Inventor	A. Chew
			Group Art Unit	1614
			Examiner Name	
			Attorney Docket Number	MWH-0002US2
Sheet	1	of	1	

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box 

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/010,802
		Filing Date	11/09/2001
		First Named Inventor	A. Chew
		Group Art Unit	1614
		Examiner Name	
Attorney Docket Number	MWH-0002US2		
Sheet 1	of 3		

RECEIVED  
 MAY 20 2002  
 PTO CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DA	BACANU S-A, DEVLIN B & ROEDER K, "The Power of Genomic Control," Am. J. Hum Genet, Vol. 66, p. 1933-44, ( May 11, 2000).	
	DB	BAILEY DS, BONDAR A & FURNESS LM, "Pharmacogenomics-It's not just pharmacogenetics," Curr Opin in Biotech, Vol 9, p. 595-601, (1998).	
	DC	BERTILSSON L, DAHL M-L, TYBRING G, "Pharmacogenetics of antidepressants: clinical aspects," Acta Psychiatr Scand, Vol 96 (Suppl 391), p. 14-21, (1997).	
	DD	CHAKRAVARTI A, "Population genetics-making sense out of sequence," Nature genetics, Vol 21, p. 56-60, ( January 1999).	
	DE	CHAKRAVARTI A, "It's raining SNPS, hallelujah?," Nature genetics, Vol. 19, p. 216-7, (July 1998).	
	DF	CLARK AG et al., "Haplotype Structure and Population Genetic Inferences from Nucleotide-Sequence Variation in Human Lipoprotein Lipase," Am J Hum Genet, Vol 63, p. 595-612, ( July 29, 1998).	
	DG	COHEN J, "Medicine: Developing prescriptions with a personal touch," Science, Vol 275, p. 776, ( February 7, 1997).	
	DH	HILL AVS et al., "Human genetic variation and its impact on public health and medicine ," Evolution in Health and Disease, Stearns S. (Ed.), Oxford University Press (New York), p. 62-74, (1999).	
	DI	JUDSON R, STEPHENS JC & WINDEMUTH A, "The predictive power of haplotypes in clinical response," Pharmacogenomics, Vol. 1 ( No. 1), p. 1-12, ( 2000).	
	DJ	KALOW W, OZDEMIR V, TANG B-K, TOTHFALUSI L & ENDRENYI L, "The Science of pharmacological variability: An essay," Clin Pharmacol Ther, Vol. 66, p. 445-7, (November 1999).	
	DK	KLEYN PW & VESELL ES, "Pharmacogenomics: Genetic Variation as a Guide to Drug Development," Science, Vol 281, p. 1820-1, ( September 18, 1998).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **3**

## **Complete if Known**

Application Number	10/010,802
Filing Date	11/09/2001
First Named Inventor	A. Chew
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	MWH-0002US2

**RECEIVED**  
**MAY 20 2002**  
**TECH CENTER 1600 P900**

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DL	KOLA I, "Complex traits, genes, polymorphisms and the drug discovery/development process," Curr Opin in Biotech, Vol 10., p. 589-92, (1999).	
	DM	KWOK P-Y & GU Z, "Single Nucleotide polymorphism libraries: why and how are we building them?," Mol Med Today, Vol. 5, p. 538-43, ( December 1999).	
	DN	LU AYH, "Drug-Metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety," Drug Metab & Disposition, Vol. 26 ( No. 12), p. 1217-1222, (1998).	
	DO	MARSHALL A, "Getting the right drug into the right patient," Nature Biotechnology, Vol 15, p. 1249-52, ( November 1997).	
	DP	MARSHALL E, "Drug Firms to create public database of genetic mutations," Science, Vol 284, p. 406-7, ( April 16, 1999).	
	DQ	MEYER UA, "Medically relevant genetic variation of drug effects," Evolution in Health and Disease, Stearns S. (Ed.), Oxford University Press (New York), p. 41-49, (1999).	
	DR	PRITCHARD JK, STEPHENS M, ROSENBERG NA & DONNELLY P, "Association mapping in structured populations," Am J Hum Genet, Vol. 67, p. 170-181, (May 26, 2000).	
	DS	ROSES AD, "Pharmacogenetics and the practice of medicine," Nature, Vol. 405, p. 857-65, ( June 15, 2000).	
	DT	STEPHENS JC, "Single-nucleotide polymorphisms , haplotypes, and their relevance to pharmacogenetics," Mol Diagnosis, Vol. 4 ( No. 4), p. 309-317, (1999).	
	DU	ULBRECHT M, HERGETH MT, WIST M, HEINRICH J, BICKEBOLLER H, WICHMANN H-E & WEISS EH, "Association of beta-2-adrenoreceptor variants with bronchial hyperresponsiveness," Am J Respir Crit Care Med, Vol. 161, p. 469-474, (2000).	
	DV	WANG DG ET AL., "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome," Science, Vol. 280, p. 1077-82, (May 15, 1998).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/010,802
<b>Filing Date</b>	11/09/2001
<b>First Named Inventor</b>	A. Chew
Group Art Unit	1614
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	MWH-00002US2

CH CENTER 1600/2900

MAY 20 2002

RECEIVED

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.